Abscisic Acid Treatment in Patients with Prediabetes

• Published in: Nutrients 2020-09, Vol.12 (10), p.2931
• Main Authors: Derosa, Giuseppe, Maffioli, Pamela, D'Angelo, Angela, Preti, Paola S, Tenore, Giancarlo, Novellino, Ettore
• Format: Article
• Language: English
• Subjects: Abscisic acid; Abscisic Acid - pharmacology; Aged; Alanine Transaminase - blood; Aspartate Aminotransferases - blood; Blood Glucose - metabolism; C-reactive protein; C-Reactive Protein - metabolism; Catheters; Cholesterol; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Creatinine; Diabetes; Dietary Supplements; Double-Blind Method; dysglycemia; Evaluation; Fasting; Female; Functional foods & nutraceuticals; Glucagon; Glucose; Glucose Clamp Technique; Glucose Intolerance - blood; Glucose tolerance; Glucose Tolerance Test; Glycated Hemoglobin A - metabolism; Hemoglobin; Homeostasis; Humans; Inflammation; Insulin; Insulin - blood; Insulin Resistance; Laboratory testing; Lipids; Male; Middle Aged; Peaches; Placebos; Plasma; plasma glucose; Postprandial Period; prediabetes; Prediabetic State - drug therapy; Randomized Controlled Trials as Topic; treatment; Veins & arteries
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu12102931

to evaluate the effects of abscisic acid (ABA), contained in dwarf peaches, on the regression of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) conditions. sixty-five patients with IFG or IGT were randomized to take ABA or placebo for 3 months. We evaluated: fasting plasma glucose (FPG), postprandial plasma glucose (PPG), glycated hemoglobin (HbA ), fasting plasma insulin (FPI), homeostatic model assessment of insulin resistance (HOMA-IR), lipid profile and high sensitivity C-reactive protein (Hs-CRP). At baseline, and after 3 months, all patients underwent an oral glucose tolerance test (OGTT), an euglycemic hyperinsulinemic clamp, and a glucagon test. a significant reduction of HbA , FPG, PPG, FPI and HOMA-IR was observed in the ABA group. After 3 months, 26.7% of patients returned to a normal glycemic status in the ABA group versus zero patients in placebo group; 20.0% were classified as IFG and 53.3% as IGT in the nutraceutical group versus 33.3% and 63.3% in the placebo group. The M value was higher in the ABA group at the end of the treatment. Finally, Hs-CRP was reduced after 3 months of ABA consumption. abscisic acid can be effective in ameliorating glyco-metabolic compensation and in reducing inflammatory status in patients with IFG or IGT.